---
schema_version: "secwatch.filing_event.v1"
accession: "0001129928-26-000009"
form_type: "8-K"
ticker: "ONCY"
cik: "0001129928"
company_name: "ONCOLYTICS BIOTECH INC"
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:36:31.789042+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Oncolytics launches Phase 2 REO 033 trial in 2L RAS-mutant MSS mCRC; preliminary data expected by end of 2026

## Summary
- Randomized Phase 2 study (REO 033) of pelareorep + bevacizumab + FOLFIRI vs bevacizumab + FOLFIRI in 30 patients per arm.
- Primary endpoint is ORR; secondary endpoints include PFS, OS, safety, and biomarker analysis; first site expected this month.
- Prior REO 022 study showed median OS 27 months and PFS 16.6 months, vs 11.2 and 5.7 months for standard of care.
- Pelareorep combination recently granted FDA Fast Track Designation for this indication.
- Lead investigator is Dr. Sanjay Goel (Rutgers Cancer Institute); preliminary data by year-end 2026.

## SEC filing metadata
- accession: 0001129928-26-000009
- form_type: 8-K
- ticker: ONCY
- cik: 0001129928
- company_name: ONCOLYTICS BIOTECH INC
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000009/0001129928-26-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000009/oncy-20260302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001129928-26-000009
- JSON: https://secwatch.observer/filing/0001129928-26-000009.json
- Plain text: https://secwatch.observer/filing/0001129928-26-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.